메뉴 건너뛰기




Volumn 18, Issue 8, 2017, Pages

Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma

Author keywords

CTLA 4; Glioblastoma; Immune checkpoint; Malignant glioma; PD 1; PD L1

Indexed keywords

AMP 224; ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; AVELUMAB; BEVACIZUMAB; BMS 936559; CARMUSTINE; CD8 ANTIGEN; CHECKPOINT KINASE INHIBITOR; DURVALUMAB; EPACADOSTAT; GALUNISERTIB; IPILIMUMAB; MEDI 0680; MONOCLONAL ANTIBODY; NIVOLUMAB; ONCOLYTIC VIRUS; PEMBROLIZUMAB; PICTILISIB; PIDILIZUMAB; PLACEBO; PROGRAMMED DEATH 1 RECEPTOR; TEMOZOLOMIDE; TICILIMUMAB; TUMOR MARKER; TUMOR VACCINE; UNCLASSIFIED DRUG; VALPROIC ACID; VARLILUMAB; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PROGRAMMED DEATH 1 LIGAND 1;

EID: 85026898078     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-017-0492-y     Document Type: Review
Times cited : (70)

References (79)
  • 1
    • 84858766182 scopus 로고    scopus 로고
    • The blockade of immune checkpoints in cancer immunotherapy
    • COI: 1:CAS:528:DC%2BC38XksVegtrw%3D, PID: 22437870
    • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.
    • (2012) Nat Rev Cancer , vol.12 , Issue.4 , pp. 252-264
    • Pardoll, D.M.1
  • 2
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • COI: 1:CAS:528:DC%2BC3cXhtVCrtrbN, PID: 20525992
    • Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.
    • (2010) N Engl J Med , vol.363 , Issue.8 , pp. 711-723
    • Hodi, F.S.1    O’Day, S.J.2    McDermott, D.F.3    Weber, R.W.4    Sosman, J.A.5    Haanen, J.B.6
  • 4
    • 84936791837 scopus 로고    scopus 로고
    • Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
    • COI: 1:CAS:528:DC%2BC2MXht12qu7%2FJ, PID: 26028407
    • Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35.
    • (2015) N Engl J Med , vol.373 , Issue.2 , pp. 123-135
    • Brahmer, J.1    Reckamp, K.L.2    Baas, P.3    Crino, L.4    Eberhardt, W.E.5    Poddubskaya, E.6
  • 5
    • 84929481481 scopus 로고    scopus 로고
    • Pembrolizumab versus ipilimumab in advanced melanoma
    • COI: 1:CAS:528:DC%2BC2MXhtFyrsbrF, PID: 25891173
    • Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32.
    • (2015) N Engl J Med , vol.372 , Issue.26 , pp. 2521-2532
    • Robert, C.1    Schachter, J.2    Long, G.V.3    Arance, A.4    Grob, J.J.5    Mortier, L.6
  • 6
    • 84963621254 scopus 로고    scopus 로고
    • Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
    • COI: 1:CAS:528:DC%2BC28XmtVOrurc%3D, PID: 27079802
    • Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275–87.
    • (2016) Nat Rev Cancer , vol.16 , Issue.5 , pp. 275-287
    • Topalian, S.L.1    Taube, J.M.2    Anders, R.A.3    Pardoll, D.M.4
  • 7
    • 85017789541 scopus 로고    scopus 로고
    • An important study that examined the frequency of and relationships between predictive biomarkers for immune checkpoint blockade efficacy in glioma. High tumor mutational burden was found to occur infrequently but was associated with MMR-deficiency. There was no significant between high mutation burden and CD8 TIL density or PD-L1 expression
    • Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, et al
    • Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, et al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol. 2017. An important study that examined the frequency of and relationships between predictive biomarkers for immune checkpoint blockade efficacy in glioma. High tumor mutational burden was found to occur infrequently but was associated with MMR-deficiency. There was no significant between high mutation burden and CD8 TIL density or PD-L1 expression.
    • (2017) Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol
  • 8
    • 85006987606 scopus 로고    scopus 로고
    • Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
    • 370ra180
    • Mathios D, Kim JE, Mangraviti A, Phallen J, Park CK, Jackson CM, et al. Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci Transl Med. 8(370):370ra180.
    • Sci Transl Med , vol.8 , Issue.370
    • Mathios, D.1    Kim, J.E.2    Mangraviti, A.3    Phallen, J.4    Park, C.K.5    Jackson, C.M.6
  • 9
    • 84962218955 scopus 로고    scopus 로고
    • Systemic tolerance mediated by melanoma brain tumors is reversible by radiotherapy and vaccination
    • COI: 1:CAS:528:DC%2BC28XktVykur4%3D, PID: 26490306
    • Jackson CM, Kochel CM, Nirschl CJ, Durham NM, Ruzevick J, Alme A, et al. Systemic tolerance mediated by melanoma brain tumors is reversible by radiotherapy and vaccination. Clin Cancer Res. 2016;22(5):1161–72.
    • (2016) Clin Cancer Res , vol.22 , Issue.5 , pp. 1161-1172
    • Jackson, C.M.1    Kochel, C.M.2    Nirschl, C.J.3    Durham, N.M.4    Ruzevick, J.5    Alme, A.6
  • 10
    • 0034596948 scopus 로고    scopus 로고
    • Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
    • COI: 1:CAS:528:DC%2BD3cXntFSlt7o%3D, PID: 11015443
    • Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–34.
    • (2000) J Exp Med , vol.192 , Issue.7 , pp. 1027-1034
    • Freeman, G.J.1    Long, A.J.2    Iwai, Y.3    Bourque, K.4    Chernova, T.5    Nishimura, H.6
  • 11
    • 5844264920 scopus 로고    scopus 로고
    • PD-L2 is a second ligand for PD-1 and inhibits T cell activation
    • COI: 1:CAS:528:DC%2BD3MXhvVaksrc%3D, PID: 11224527
    • Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261–8.
    • (2001) Nat Immunol , vol.2 , Issue.3 , pp. 261-268
    • Latchman, Y.1    Wood, C.R.2    Chernova, T.3    Chaudhary, D.4    Borde, M.5    Chernova, I.6
  • 12
    • 57849168934 scopus 로고    scopus 로고
    • Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
    • COI: 1:CAS:528:DC%2BD1cXhsVenu73N, PID: 19043418
    • Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10(1):29–37.
    • (2009) Nat Immunol , vol.10 , Issue.1 , pp. 29-37
    • Blackburn, S.D.1    Shin, H.2    Haining, W.N.3    Zou, T.4    Workman, C.J.5    Polley, A.6
  • 13
    • 84937837169 scopus 로고    scopus 로고
    • Molecular and cellular insights into T cell exhaustion
    • COI: 1:CAS:528:DC%2BC2MXht1ensLvE, PID: 26205583
    • Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–99.
    • (2015) Nat Rev Immunol , vol.15 , Issue.8 , pp. 486-499
    • Wherry, E.J.1    Kurachi, M.2
  • 14
    • 84994802263 scopus 로고    scopus 로고
    • Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer
    • COI: 1:CAS:528:DC%2BC28XhvF2ks77I, PID: 27718847
    • Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.
    • (2016) N Engl J Med , vol.375 , Issue.19 , pp. 1823-1833
    • Reck, M.1    Rodriguez-Abreu, D.2    Robinson, A.G.3    Hui, R.4    Csoszi, T.5    Fulop, A.6
  • 15
    • 84946607195 scopus 로고    scopus 로고
    • Nivolumab versus everolimus in advanced renal-cell carcinoma
    • COI: 1:CAS:528:DC%2BC28XjsFyhsrg%3D, PID: 26406148
    • Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.
    • (2015) N Engl J Med , vol.373 , Issue.19 , pp. 1803-1813
    • Motzer, R.J.1    Escudier, B.2    McDermott, D.F.3    George, S.4    Hammers, H.J.5    Srinivas, S.6
  • 17
    • 20044366163 scopus 로고    scopus 로고
    • Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
    • COI: 1:CAS:528:DC%2BD2MXit1Wksbk%3D, PID: 15758009
    • Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.
    • (2005) N Engl J Med , vol.352 , Issue.10 , pp. 987-996
    • Stupp, R.1    Mason, W.P.2    van den Bent, M.J.3    Weller, M.4    Fisher, B.5    Taphoorn, M.J.6
  • 19
    • 85007295572 scopus 로고    scopus 로고
    • Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease
    • COI: 1:CAS:528:DC%2BC28XitVGnt7zO, PID: 27663893
    • Liu J, Blake SJ, Yong MC, Harjunpaa H, Ngiow SF, Takeda K, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6(12):1382–99.
    • (2016) Cancer Discov , vol.6 , Issue.12 , pp. 1382-1399
    • Liu, J.1    Blake, S.J.2    Yong, M.C.3    Harjunpaa, H.4    Ngiow, S.F.5    Takeda, K.6
  • 21
    • 84883192286 scopus 로고    scopus 로고
    • Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas
    • COI: 1:CAS:528:DC%2BC3sXhtlGnu7zJ, PID: 23737488
    • Xu S, Shao QQ, Sun JT, Yang N, Xie Q, Wang DH, et al. Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas. Neuro-Oncology. 2013;15(9):1160–72.
    • (2013) Neuro-Oncology , vol.15 , Issue.9 , pp. 1160-1172
    • Xu, S.1    Shao, Q.Q.2    Sun, J.T.3    Yang, N.4    Xie, Q.5    Wang, D.H.6
  • 22
    • 84904061991 scopus 로고    scopus 로고
    • Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors
    • COI: 1:CAS:528:DC%2BC2cXhslKnsr%2FK, PID: 24691018
    • Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias A, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res. 2014;20(20):5290–301.
    • (2014) Clin Cancer Res , vol.20 , Issue.20 , pp. 5290-5301
    • Wainwright, D.A.1    Chang, A.L.2    Dey, M.3    Balyasnikova, I.V.4    Kim, C.K.5    Tobias, A.6
  • 23
    • 85010297255 scopus 로고    scopus 로고
    • Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas
    • COI: 1:CAS:528:DC%2BC2sXhs1Wntg%3D%3D, PID: 27358487
    • Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E, et al. Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin Cancer Res. 2017;23(1):124–36.
    • (2017) Clin Cancer Res , vol.23 , Issue.1 , pp. 124-136
    • Kim, J.E.1    Patel, M.A.2    Mangraviti, A.3    Kim, E.S.4    Theodros, D.5    Velarde, E.6
  • 24
    • 0027285735 scopus 로고
    • Inducible T cell antigen 4-1BB. Analysis of expression and function
    • COI: 1:CAS:528:DyaK3sXhsVGntLg%3D, PID: 7678621
    • Pollok KE, Kim YJ, Zhou Z, Hurtado J, Kim KK, Pickard RT, et al. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol. 1993;150(3):771–81.
    • (1993) J Immunol , vol.150 , Issue.3 , pp. 771-781
    • Pollok, K.E.1    Kim, Y.J.2    Zhou, Z.3    Hurtado, J.4    Kim, K.K.5    Pickard, R.T.6
  • 25
    • 0031007143 scopus 로고    scopus 로고
    • Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
    • Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997 Jun;3(6):682–5.
    • (1997) Nat Med , vol.3 , Issue.6 , pp. 682-685
    • Melero, I.1    Shuford, W.W.2    Newby, S.A.3    Aruffo, A.4    Ledbetter, J.A.5    Hellstrom, K.E.6
  • 26
    • 84904207094 scopus 로고    scopus 로고
    • Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model
    • PID: 25013914
    • Belcaid Z, Phallen JA, Zeng J, See AP, Mathios D, Gottschalk C, et al. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLoS One. 2014;9(7):e101764.
    • (2014) PLoS One , vol.9 , Issue.7
    • Belcaid, Z.1    Phallen, J.A.2    Zeng, J.3    See, A.P.4    Mathios, D.5    Gottschalk, C.6
  • 27
    • 84937517015 scopus 로고    scopus 로고
    • The role of IDO in brain tumor immunotherapy
    • COI: 1:CAS:528:DC%2BC2cXitFOrs7bO
    • Zhai L, Lauing KL, Chang AL, Dey M, Qian J, Cheng Y, et al. The role of IDO in brain tumor immunotherapy. J Neuro-Oncol. 2015;123(3):395–403.
    • (2015) J Neuro-Oncol , vol.123 , Issue.3 , pp. 395-403
    • Zhai, L.1    Lauing, K.L.2    Chang, A.L.3    Dey, M.4    Qian, J.5    Cheng, Y.6
  • 29
    • 78649880396 scopus 로고    scopus 로고
    • An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells
    • COI: 1:CAS:528:DC%2BC3cXhtFSntL7F, PID: 20720200
    • Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010;185(6):3190–8.
    • (2010) J Immunol , vol.185 , Issue.6 , pp. 3190-3198
    • Mezrich, J.D.1    Fechner, J.H.2    Zhang, X.3    Johnson, B.P.4    Burlingham, W.J.5    Bradfield, C.A.6
  • 30
    • 84869232447 scopus 로고    scopus 로고
    • IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival
    • COI: 1:CAS:528:DC%2BC38Xhs12jur7I, PID: 22932670
    • Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger B, et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res. 2012;18(22):6110–21.
    • (2012) Clin Cancer Res , vol.18 , Issue.22 , pp. 6110-6121
    • Wainwright, D.A.1    Balyasnikova, I.V.2    Chang, A.L.3    Ahmed, A.U.4    Moon, K.S.5    Auffinger, B.6
  • 31
    • 85007439991 scopus 로고    scopus 로고
    • Dendritic cell-based immunotherapy
    • COI: 1:CAS:528:DC%2BC28XitFOhs7bM, PID: 28025976
    • Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res. 2017;27(1):74–95.
    • (2017) Cell Res , vol.27 , Issue.1 , pp. 74-95
    • Sabado, R.L.1    Balan, S.2    Bhardwaj, N.3
  • 33
    • 85018815533 scopus 로고    scopus 로고
    • Dendritic cell based vaccination strategy: an evolving paradigm
    • Filley AC, Dey M. Dendritic cell based vaccination strategy: an evolving paradigm. J Neurooncol 2017 22.
    • (2017) J Neurooncol , vol.22
    • Filley, A.C.1    Dey, M.2
  • 34
    • 0035107548 scopus 로고    scopus 로고
    • Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration
    • COI: 1:CAS:528:DC%2BD3MXhsFSrtLs%3D, PID: 11221866, Feb 1
    • Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 2001 Feb 1;61(3):842–7.
    • (2001) Cancer Res , vol.61 , Issue.3 , pp. 842-847
    • Yu, J.S.1    Wheeler, C.J.2    Zeltzer, P.M.3    Ying, H.4    Finger, D.N.5    Lee, P.K.6
  • 35
    • 0242329784 scopus 로고    scopus 로고
    • Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial
    • COI: 1:CAS:528:DC%2BD3sXns1Cmu7k%3D, PID: 14520441
    • Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, Kobayashi T, et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer. 2003;89(7):1172–9.
    • (2003) Br J Cancer , vol.89 , Issue.7 , pp. 1172-1179
    • Yamanaka, R.1    Abe, T.2    Yajima, N.3    Tsuchiya, N.4    Homma, J.5    Kobayashi, T.6
  • 36
    • 3142692559 scopus 로고    scopus 로고
    • Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma
    • COI: 1:CAS:528:DC%2BD2cXls1Omt7o%3D, PID: 15256471
    • Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004;64(14):4973–9.
    • (2004) Cancer Res , vol.64 , Issue.14 , pp. 4973-4979
    • Yu, J.S.1    Liu, G.2    Ying, H.3    Yong, W.H.4    Black, K.L.5    Wheeler, C.J.6
  • 37
    • 79951978155 scopus 로고    scopus 로고
    • Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma
    • COI: 1:CAS:528:DC%2BC3MXit1yhurs%3D, PID: 21149657
    • Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011;29(3):330–6.
    • (2011) J Clin Oncol , vol.29 , Issue.3 , pp. 330-336
    • Okada, H.1    Kalinski, P.2    Ueda, R.3    Hoji, A.4    Kohanbash, G.5    Donegan, T.E.6
  • 38
    • 79952711945 scopus 로고    scopus 로고
    • Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy
    • COI: 1:CAS:528:DC%2BC3MXjtFCht7w%3D, PID: 21135147
    • Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011;17(6):1603–15.
    • (2011) Clin Cancer Res , vol.17 , Issue.6 , pp. 1603-1615
    • Prins, R.M.1    Soto, H.2    Konkankit, V.3    Odesa, S.K.4    Eskin, A.5    Yong, W.H.6
  • 39
    • 85071335009 scopus 로고    scopus 로고
    • PD-1 blockade enhances the vaccination-induced immune response in glioma
    • PID: 27453950
    • Antonios JP, Soto H, Everson RG, Orpilla J, Moughon D, Shin N, et al. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight. 2016;1(10):e87059.
    • (2016) JCI Insight , vol.1 , Issue.10
    • Antonios, J.P.1    Soto, H.2    Everson, R.G.3    Orpilla, J.4    Moughon, D.5    Shin, N.6
  • 40
    • 85021790700 scopus 로고    scopus 로고
    • Autologous heat shock protein peptide vaccination for newly diagnosed glioblastoma: impact of peripheral PD-L1 expression on response to therapy
    • Bloch O, Lim M, Sughrue ME, Komotar RJ, Abrahams JM, O’Rourke DM, et al. Autologous heat shock protein peptide vaccination for newly diagnosed glioblastoma: impact of peripheral PD-L1 expression on response to therapy. Clin Cancer Res 2017 13.
    • (2017) Clin Cancer Res , vol.13
    • Bloch, O.1    Lim, M.2    Sughrue, M.E.3    Komotar, R.J.4    Abrahams, J.M.5    O’Rourke, D.M.6
  • 41
    • 85014550014 scopus 로고    scopus 로고
    • Oncolytic virotherapy for the treatment of malignant glioma
    • COI: 1:CAS:528:DC%2BC2sXjvVaiurg%3D, PID: 28265902
    • Foreman PM, Friedman GK, Cassady KA, Markert JM. Oncolytic virotherapy for the treatment of malignant glioma. Neurotherapeutics. 2017;14(2):333–44.
    • (2017) Neurotherapeutics , vol.14 , Issue.2 , pp. 333-344
    • Foreman, P.M.1    Friedman, G.K.2    Cassady, K.A.3    Markert, J.M.4
  • 42
    • 84883642231 scopus 로고    scopus 로고
    • Oncolytic viruses as therapeutic cancer vaccines
    • Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, et al. ;12(1):103. -4598-12-103
    • Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, et al. Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer. 2013;12(1):103. -4598-12-103
    • (2013) Mol Cancer
  • 43
    • 34948820602 scopus 로고    scopus 로고
    • Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
    • COI: 1:CAS:528:DC%2BD2sXhtVSgtr3E, PID: 17704786
    • Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050–9.
    • (2007) Nat Med , vol.13 , Issue.9 , pp. 1050-1059
    • Apetoh, L.1    Ghiringhelli, F.2    Tesniere, A.3    Obeid, M.4    Ortiz, C.5    Criollo, A.6
  • 44
    • 1242315588 scopus 로고    scopus 로고
    • Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
    • PID: 14967443
    • Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58(3):862–70.
    • (2004) Int J Radiat Oncol Biol Phys , vol.58 , Issue.3 , pp. 862-870
    • Demaria, S.1    Ng, B.2    Devitt, M.L.3    Babb, J.S.4    Kawashima, N.5    Liebes, L.6
  • 45
    • 84983353116 scopus 로고    scopus 로고
    • Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen
    • COI: 1:CAS:528:DC%2BC2MXlvFemtLg%3D, PID: 25527358
    • Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res. 2015;3(4):345–55.
    • (2015) Cancer Immunol Res , vol.3 , Issue.4 , pp. 345-355
    • Sharabi, A.B.1    Nirschl, C.J.2    Kochel, C.M.3    Nirschl, T.R.4    Francica, B.J.5    Velarde, E.6
  • 46
    • 84893876109 scopus 로고    scopus 로고
    • Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
    • COI: 1:CAS:528:DC%2BC2cXis1ertbc%3D, PID: 24382348
    • Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687–95.
    • (2014) J Clin Invest , vol.124 , Issue.2 , pp. 687-695
    • Deng, L.1    Liang, H.2    Burnette, B.3    Beckett, M.4    Darga, T.5    Weichselbaum, R.R.6
  • 47
    • 84926525215 scopus 로고    scopus 로고
    • Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
    • COI: 1:CAS:528:DC%2BC2MXktVCnsbw%3D, PID: 25754329
    • Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–7.
    • (2015) Nature , vol.520 , Issue.7547 , pp. 373-377
    • Twyman-Saint Victor, C.1    Rech, A.J.2    Maity, A.3    Rengan, R.4    Pauken, K.E.5    Stelekati, E.6
  • 48
    • 84877581852 scopus 로고    scopus 로고
    • Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas
    • COI: 1:CAS:528:DC%2BC3sXivFyku7k%3D, PID: 23462419
    • Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):343–9.
    • (2013) Int J Radiat Oncol Biol Phys , vol.86 , Issue.2 , pp. 343-349
    • Zeng, J.1    See, A.P.2    Phallen, J.3    Jackson, C.M.4    Belcaid, Z.5    Ruzevick, J.6
  • 49
    • 84887481716 scopus 로고    scopus 로고
    • CSF-1R inhibition alters macrophage polarization and blocks glioma progression
    • COI: 1:CAS:528:DC%2BC3sXhsV2jsr3N, PID: 24056773
    • Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264–72.
    • (2013) Nat Med , vol.19 , Issue.10 , pp. 1264-1272
    • Pyonteck, S.M.1    Akkari, L.2    Schuhmacher, A.J.3    Bowman, R.L.4    Sevenich, L.5    Quail, D.F.6
  • 50
    • 84943241524 scopus 로고    scopus 로고
    • Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
    • PID: 25355681, An extensive biomarker study that analyzed TIL density and PD-L1 expression levels in GBM. PD-L1 gene expression was not found to be associated with OS
    • Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wohrer A, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-Oncology. 2015;17(8):1064–75. An extensive biomarker study that analyzed TIL density and PD-L1 expression levels in GBM. PD-L1 gene expression was not found to be associated with OS
    • (2015) Neuro-Oncology , vol.17 , Issue.8 , pp. 1064-1075
    • Berghoff, A.S.1    Kiesel, B.2    Widhalm, G.3    Rajky, O.4    Ricken, G.5    Wohrer, A.6
  • 51
    • 0029114319 scopus 로고
    • Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma
    • COI: 1:CAS:528:DyaK2MXpsVWms74%3D, PID: 7635563
    • Yamada N, Kato M, Yamashita H, Nister M, Miyazono K, Heldin CH, et al. Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma. Int J Cancer. 1995;62(4):386–92.
    • (1995) Int J Cancer , vol.62 , Issue.4 , pp. 386-392
    • Yamada, N.1    Kato, M.2    Yamashita, H.3    Nister, M.4    Miyazono, K.5    Heldin, C.H.6
  • 52
    • 84946570713 scopus 로고    scopus 로고
    • TGF-beta signaling and its targeting for glioma treatment
    • COI: 1:CAS:528:DC%2BC28XhsFWlurnF, PID: 26045979
    • Han J, Alvarez-Breckenridge CA, Wang QE, Yu J. TGF-beta signaling and its targeting for glioma treatment. Am J Cancer Res. 2015;5(3):945–55.
    • (2015) Am J Cancer Res , vol.5 , Issue.3 , pp. 945-955
    • Han, J.1    Alvarez-Breckenridge, C.A.2    Wang, Q.E.3    Yu, J.4
  • 53
    • 84928761118 scopus 로고    scopus 로고
    • Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
    • COI: 1:CAS:528:DC%2BC2MXls1Wmtbg%3D, PID: 25765070, A key clinical study that determined how tumor mutational burden impacts responses to anti-PD-1 therapy in NSCLC patients
    • Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–8. A key clinical study that determined how tumor mutational burden impacts responses to anti-PD-1 therapy in NSCLC patients
    • (2015) Science , vol.348 , Issue.6230 , pp. 124-128
    • Rizvi, N.A.1    Hellmann, M.D.2    Snyder, A.3    Kvistborg, P.4    Makarov, V.5    Havel, J.J.6
  • 54
    • 84920956732 scopus 로고    scopus 로고
    • PD-1 blockade induces responses by inhibiting adaptive immune resistance
    • COI: 1:CAS:528:DC%2BC2cXitFanu7jL, PID: 25428505, Pivotal study demonstrating the association between the density of a pre-existing CD8 TIL infiltrate and therapeutic responses to pembrolizumab in melanoma patients
    • Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71. Pivotal study demonstrating the association between the density of a pre-existing CD8 TIL infiltrate and therapeutic responses to pembrolizumab in melanoma patients
    • (2014) Nature , vol.515 , Issue.7528 , pp. 568-571
    • Tumeh, P.C.1    Harview, C.L.2    Yearley, J.H.3    Shintaku, I.P.4    Taylor, E.J.5    Robert, L.6
  • 55
    • 84962301577 scopus 로고    scopus 로고
    • Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
    • COI: 1:CAS:528:DC%2BC28XksFCht70%3D, PID: 26940869
    • McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463–9.
    • (2016) Science , vol.351 , Issue.6280 , pp. 1463-1469
    • McGranahan, N.1    Furness, A.J.2    Rosenthal, R.3    Ramskov, S.4    Lyngaa, R.5    Saini, S.K.6
  • 56
    • 84880507665 scopus 로고    scopus 로고
    • Mutational heterogeneity in cancer and the search for new cancer-associated genes
    • COI: 1:CAS:528:DC%2BC3sXpsFSgsbo%3D, PID: 23770567
    • Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–8.
    • (2013) Nature , vol.499 , Issue.7457 , pp. 214-218
    • Lawrence, M.S.1    Stojanov, P.2    Polak, P.3    Kryukov, G.V.4    Cibulskis, K.5    Sivachenko, A.6
  • 57
  • 58
    • 84932628341 scopus 로고    scopus 로고
    • PD-1 blockade in tumors with mismatch-repair deficiency
    • COI: 1:CAS:528:DC%2BC2MXhtFyrsbrI, PID: 26028255
    • Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.
    • (2015) N Engl J Med , vol.372 , Issue.26 , pp. 2509-2520
    • Le, D.T.1    Uram, J.N.2    Wang, H.3    Bartlett, B.R.4    Kemberling, H.5    Eyring, A.D.6
  • 59
    • 84976467739 scopus 로고    scopus 로고
    • Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency
    • PID: 27001570
    • Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol. 2016;34(19):2206–11.
    • (2016) J Clin Oncol , vol.34 , Issue.19 , pp. 2206-2211
    • Bouffet, E.1    Larouche, V.2    Campbell, B.B.3    Merico, D.4    de Borja, R.5    Aronson, M.6
  • 60
    • 84995511734 scopus 로고    scopus 로고
    • Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy
    • PID: 27683556
    • Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, Perry A, et al. Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discov. 2016;6(11):1230–6.
    • (2016) Cancer Discov , vol.6 , Issue.11 , pp. 1230-1236
    • Johanns, T.M.1    Miller, C.A.2    Dorward, I.G.3    Tsien, C.4    Chang, E.5    Perry, A.6
  • 61
    • 84892373020 scopus 로고    scopus 로고
    • Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
    • COI: 1:CAS:528:DC%2BC2cXktVyktQ%3D%3D, PID: 24336570
    • Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167):189–93.
    • (2014) Science , vol.343 , Issue.6167 , pp. 189-193
    • Johnson, B.E.1    Mazor, T.2    Hong, C.3    Barnes, M.4    Aihara, K.5    McLean, C.Y.6
  • 62
    • 84862859820 scopus 로고    scopus 로고
    • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    • COI: 1:CAS:528:DC%2BC38XhtV2rs7fN, PID: 22658127, One of the first studies demonstrating the correlation between tumor PD-L1 expression and anti-PD-1 therapy efficacy. This was a phase 1 study that examined the safety and efficacy of nivolumab in multiple tumor types including advanced melanoma, NSCLC, castration-resistant prostate cancer, RCC, and colorectal canccer
    • Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, DF MD, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54. One of the first studies demonstrating the correlation between tumor PD-L1 expression and anti-PD-1 therapy efficacy. This was a phase 1 study that examined the safety and efficacy of nivolumab in multiple tumor types including advanced melanoma, NSCLC, castration-resistant prostate cancer, RCC, and colorectal canccer
    • (2012) N Engl J Med , vol.366 , Issue.26 , pp. 2443-2454
    • Topalian, S.L.1    Hodi, F.S.2    Brahmer, J.R.3    Gettinger, S.N.4    Smith, D.C.5    Df, M.D.6
  • 64
    • 84961618736 scopus 로고    scopus 로고
    • Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas
    • PID: 26771840
    • Zeng J, Zhang XK, Chen HD, Zhong ZH, Wu QL, Lin SX. Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. Oncotarget. 2016;7(8):8944–55.
    • (2016) Oncotarget , vol.7 , Issue.8 , pp. 8944-8955
    • Zeng, J.1    Zhang, X.K.2    Chen, H.D.3    Zhong, Z.H.4    Wu, Q.L.5    Lin, S.X.6
  • 66
    • 84994559117 scopus 로고    scopus 로고
    • Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma
    • PID: 27999734
    • Wang Z, Zhang C, Liu X, Wang Z, Sun L, Li G, et al. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. Oncoimmunology. 2016;5(11):e1196310.
    • (2016) Oncoimmunology , vol.5 , Issue.11
    • Wang, Z.1    Zhang, C.2    Liu, X.3    Wang, Z.4    Sun, L.5    Li, G.6
  • 67
    • 85013230631 scopus 로고    scopus 로고
    • PD-L1 expression and combined status of PD-L1/PD-1-positive tumor infiltrating mononuclear cell density predict prognosis in glioblastoma patients
    • Han J, Hong Y, Lee YS. PD-L1 expression and combined status of PD-L1/PD-1-positive tumor infiltrating mononuclear cell density predict prognosis in glioblastoma patients. J Pathol Transl Med. 2017 Jan;51(1):40–8.
    • (2017) J Pathol Transl Med , vol.51 , Issue.1 , pp. 40-48
    • Han, J.1    Hong, Y.2    Lee, Y.S.3
  • 68
    • 84879484111 scopus 로고    scopus 로고
    • Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages
    • COI: 1:CAS:528:DC%2BC3sXpsVyns7o%3D, PID: 23613317
    • Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res. 2013;19(12):3165–75.
    • (2013) Clin Cancer Res , vol.19 , Issue.12 , pp. 3165-3175
    • Bloch, O.1    Crane, C.A.2    Kaur, R.3    Safaee, M.4    Rutkowski, M.J.5    Parsa, A.T.6
  • 69
    • 84892866206 scopus 로고    scopus 로고
    • Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma
    • COI: 1:CAS:528:DC%2BC3sXhvF2kur7L, PID: 24145345
    • Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013;31(34):4311–8.
    • (2013) J Clin Oncol , vol.31 , Issue.34 , pp. 4311-4318
    • Weber, J.S.1    Kudchadkar, R.R.2    Yu, B.3    Gallenstein, D.4    Horak, C.E.5    Inzunza, H.D.6
  • 70
  • 71
    • 84948451779 scopus 로고    scopus 로고
    • Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
    • COI: 1:CAS:528:DC%2BC2MXhvFamtL3K, PID: 26541606
    • Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084–9.
    • (2015) Science , vol.350 , Issue.6264 , pp. 1084-1089
    • Sivan, A.1    Corrales, L.2    Hubert, N.3    Williams, J.B.4    Aquino-Michaels, K.5    Earley, Z.M.6
  • 72
    • 84948461699 scopus 로고    scopus 로고
    • Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
    • COI: 1:CAS:528:DC%2BC2MXhvFamtL3J, PID: 26541610
    • Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079–84.
    • (2015) Science , vol.350 , Issue.6264 , pp. 1079-1084
    • Vetizou, M.1    Pitt, J.M.2    Daillere, R.3    Lepage, P.4    Waldschmitt, N.5    Flament, C.6
  • 73
    • 80051693219 scopus 로고    scopus 로고
    • Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide
    • COI: 1:CAS:528:DC%2BC3MXhtVajs7fK, PID: 21737504
    • Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011;17(16):5473–80.
    • (2011) Clin Cancer Res , vol.17 , Issue.16 , pp. 5473-5480
    • Grossman, S.A.1    Ye, X.2    Lesser, G.3    Sloan, A.4    Carraway, H.5    Desideri, S.6
  • 74
    • 0028917333 scopus 로고
    • Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas
    • COI: 1:STN:280:DyaK2M3ktVansw%3D%3D, PID: 7723496
    • Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group Lancet. 1995;345(8956):1008–12.
    • (1995) The Polymer-brain Tumor Treatment Group Lancet , vol.345 , Issue.8956 , pp. 1008-1012
    • Brem, H.1    Piantadosi, S.2    Burger, P.C.3    Walker, M.4    Selker, R.5    Vick, N.A.6
  • 75
    • 84873129162 scopus 로고    scopus 로고
    • The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells
    • COI: 1:CAS:528:DC%2BC3sXhvFGqsr0%3D
    • Yovino S, Kleinberg L, Grossman SA, Narayanan M, Ford E. The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Investig. 2013;31(2):140–4.
    • (2013) Cancer Investig , vol.31 , Issue.2 , pp. 140-144
    • Yovino, S.1    Kleinberg, L.2    Grossman, S.A.3    Narayanan, M.4    Ford, E.5
  • 76
    • 0017804612 scopus 로고
    • Analysis of treatment in childhood leukemia. IV. The critical association between dose fractionation and immunosuppression induced by cranial irradiation
    • COI: 1:STN:280:DyaE1c7gsFSrtQ%3D%3D, PID: 272224
    • MacLennan IC, Kay HE. Analysis of treatment in childhood leukemia. IV. The critical association between dose fractionation and immunosuppression induced by cranial irradiation. Cancer. 1978;41(1):108–11.
    • (1978) Cancer , vol.41 , Issue.1 , pp. 108-111
    • MacLennan, I.C.1    Kay, H.E.2
  • 77
    • 67649966553 scopus 로고    scopus 로고
    • Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg
    • COI: 1:CAS:528:DC%2BD1MXltlegtbo%3D, PID: 19337997
    • Biollaz G, Bernasconi L, Cretton C, Puntener U, Frei K, Fontana A, et al. Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg. Eur J Immunol. 2009;39(5):1323–33.
    • (2009) Eur J Immunol , vol.39 , Issue.5 , pp. 1323-1333
    • Biollaz, G.1    Bernasconi, L.2    Cretton, C.3    Puntener, U.4    Frei, K.5    Fontana, A.6
  • 78
    • 73149092567 scopus 로고    scopus 로고
    • Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
    • COI: 1:CAS:528:DC%2BD1MXhsFSnu7vN, PID: 19934295
    • Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–20.
    • (2009) Clin Cancer Res , vol.15 , Issue.23 , pp. 7412-7420
    • Wolchok, J.D.1    Hoos, A.2    O'Day, S.3    Weber, J.S.4    Hamid, O.5    Lebbe, C.6
  • 79
    • 84960956996 scopus 로고    scopus 로고
    • Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
    • PID: 26545842
    • Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015;16(15):e534–42.
    • (2015) Lancet Oncol , vol.16 , Issue.15 , pp. e534-e542
    • Okada, H.1    Weller, M.2    Huang, R.3    Finocchiaro, G.4    Gilbert, M.R.5    Wick, W.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.